Search - tctmd.com

Displaying 181 - 200 of 214

Sort: Relevancy | Date

News Daily News

FFR Assessment for Small Vessel Disease Improves Outcomes

L.A. McKeown

March 23, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

Medical Societies Issue Position Paper in Anticipation of Transcatheter Valve Availability

L.A. McKeown

March 06, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Industry News

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

November 08, 2011

News Conference News

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

November 08, 2011

News Conference News

ZES, EES Noninferior to PES

November 07, 2011

News Conference News

ZES Match or Exceed Performance of Earlier DES

November 07, 2011

News Industry News

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

November 07, 2011

News Conference News

DES and Stent Thrombosis Revisited

November 07, 2011

News Conference News

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

November 06, 2011

News Industry News

Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

November 04, 2011

News Daily News

Six Months Sufficient for Dual Antiplatelet Therapy

Jason Kahn

October 17, 2011

News Daily News

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

September 14, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Daily News

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

Leah Lawrence

August 23, 2011

Advertisement

FFR Assessment for Small Vessel Disease Improves Outcomes

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

Celecoxib Enhances DES Efficacy, But at Clinical Cost

Medical Societies Issue Position Paper in Anticipation of Transcatheter Valve Availability

SCAAR: Second-Generation DES Improve Hard Outcomes

Some New-Generation Stents Prone to Longitudinal Distortion

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

RAPID GENE: Validation of Point-of-Care Genetic Testing

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

ZES, EES Noninferior to PES

ZES Match or Exceed Performance of Earlier DES

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

DES and Stent Thrombosis Revisited

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

Six Months Sufficient for Dual Antiplatelet Therapy

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

Long-term Antiplatelet Therapy: All Risk, No Benefit

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content